Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen binding proteins that bind EGFR

An antibody, fully human antibody technology, applied in the direction of anti-animal/human immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, immunoglobulin, etc., can solve the limitation and hinder effective drugs use, etc.

Inactive Publication Date: 2015-09-16
SORRENTO THERAPEUTICS INC
View PDF28 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chemotherapy, in particular, causes numerous side effects, in some cases severe enough to limit the doses that can be administered, thus preventing the use of potentially effective drugs
In addition, cancers tend to become resistant to chemotherapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen binding proteins that bind EGFR
  • Antigen binding proteins that bind EGFR
  • Antigen binding proteins that bind EGFR

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0151] Full-length IgGs were purified using protein A, and their purity was checked by SDS-PAGE. In terms of binding specificity (compared to soluble EGFR and EGFR-expressing cell lines), binding affinity (Biacore), inhibition of EGF binding to soluble EGFR, EGF-stimulated EGFR phosphorylation and cell proliferation in EGFR-expressing cell lines, Characterization of purified antibodies. Anti-EGFR antibodies were converted to IgGs and expressed in 293 cells. Purification with protein A yielded expression levels in the range of 0.86-5.5 μg / ml. This antibody has complete heavy and light chains. Five of these (A5, A6, B1, B4 and B5) bound strongly to soluble EGFR and EGFR expressed in the cell lines. One antibody (D6) bound moderately to both soluble EGFR and EGFR-expressing cell lines. ELISA analysis showed that the six binding proteins also blocked the binding of ligand EGF to soluble EGFR.

[0152] Three binding proteins (A5, A6 and B5) showed -10% inhibition in EGF-stimul...

Embodiment 2

[0154] This example demonstrates the production of anti-EGFR antibodies. Anti-EGFR antibodies were produced by transient transfection of Chinese hamster ovary subclone S (CHO-S) cells (Life Technologies) with expression vectors containing anti-human EGFR IgG1 heavy chain and light chain structural genes.

[0155] Cell lines were maintained in shake flasks and routinely passaged every 3-4 days using CHO-S-SFMII medium (Life Technologies). Two plasmids were used to generate transient pools: one carrying the heavy chain and the other carrying the light chain. The vector was co-transfected into host cell lines using 25kd linear ethyleneimine (PEI, Polysciences).

[0156] Briefly, PEI was diluted in OptiPro SFM (Life Technologies) and added to plasmid DNA that had been diluted with an equal volume of OptiPro SFM. The PEI / DNA mixture was incubated for 5-10 minutes before being added to the CHO-S cell suspension. Cultures were grown at 37°C for predetermined periods of time and th...

Embodiment 3

[0158] This example demonstrates cell binding in vitro data for one of the initial screening steps for several antibodies in this disclosure, including A6. This example demonstrates the ability of an anti-EGFR antibody to bind to the EGF receptor expressed on the surface of A431 cells (essential for the antagonistic properties of the antibody), and to compare with commercially available cetuximab (cetuximab ( ))Compare. Here, 100000 A431 cells were aliquoted into a test tube containing 100 μl of FACS Buffer (PBS+2% FBS). Cells were pelleted and resuspended in triplicate in 100 μl FACS Buffer containing 5 μg / ml of the indicated antibody. After culturing for half an hour, the cells were washed once with FACS Buffer, and resuspended in 100 μl of PE-linked goat anti-human IgG (γ-chain specific) secondary antibody (Southern Biotech Cat#2040-09). The cells were cultured again for half an hour, washed once with FACS Buffer, resuspended in 300 μl FACS Buffer, and the median fluores...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

There is disclosed compositions and methods relating to or derived from anti-EGFR antibodies. More specifically, there is disclosed fully human antibodies that bind EGFR, EGFR-binding fragments and derivatives of such antibodies, and EGFR-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having EGFR-related disorders or conditions.

Description

technical field [0001] The present disclosure provides compositions and methods involving or derived from anti-EGFR antibodies. More specifically, the present disclosure provides human antibodies that bind to EGFR, fragments and derivatives of said antibodies capable of binding to EGFR, and EGFR-binding polypeptides comprising said fragments. Further, the present disclosure provides fragments, derivatives and polypeptides of antibodies and methods of using the antibodies, fragments of the antibodies and derivatives and polypeptides thereof, including treating or diagnosing a subject suffering from an EGFR-related disease or condition. Background technique [0002] Cancer remains one of the deadliest threats to human health. In the United States, nearly 1.3 million new patients develop cancer each year, and cancer is the second leading cause of death after heart disease, accounting for 1 in every 4 deaths. Moreover, it is predicted that within 5 years, cancer will overtake ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28
CPCC07K16/2863C07K2317/73C07K2317/92C07K2317/21A61K2039/505C07K2317/732C07K2317/76A61P35/00
Inventor 周贺钺兰迪·加斯特沃特芭芭拉·A·斯旺森约翰·迪克森·葛雷
Owner SORRENTO THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com